101.34 0.00 (0.00%)
After hours: 4:25PM EST
|Bid||101.42 x 800|
|Ask||101.51 x 1000|
|Day's range||100.55 - 101.71|
|52-week range||78.35 - 103.00|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||48.30|
|Forward dividend & yield||0.28 (0.28%)|
|Ex-dividend date||14 Jan 2020|
|1y target est||N/A|
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Monday, January 27, 2020, after market close, the Company will release fourth quarter 2019 results. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call.
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 3:30 p.m. PT at the Westin St. Francis in San Francisco.
PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug Administration (FDA) approval. This solution is the first commercially available assay for screening newborns affected by Duchenne muscular dystrophy (DMD).
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.